

Transgene Announces Investor Meetings for January 2022

Strasbourg, December 17, 2021 - 05:45 pm CET

TRANSGENE (Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.

Transgene will meet institutional investors at **the 11th Annual LifeSci Advisors Corporate Access Event (virtual event) from January 5th to 7th, 2022.**

The Company will also attend:

- **25th ODDO BHF Digital Forum** (virtual): January 6, 7, 10 and 11, 2022
- **Biotech Showcase Investor Conference** (virtual):
 - January 10 to 12, 2022, in conjunction with the **J.P. Morgan Healthcare conference**
 - January 17 to 19, 2022
- **Biomed Event** (Paris): January 26, 2022

Contacts

Transgene:

Lucie Larguier / Jean-Philippe Del

Director Corporate Communications & IR

+33 (0)3 88 27 91 04 / 00

investorrelations@transgene.fr

Media Transgene:

MEDiSTRAVA Consulting

David Dible/Sylvie Berrebi

+44 (0)7714 306525

transgene@medistrava.com

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the *myvac*[®] platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO[™] platform).

With Transgene's *myvac*[®] platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*[®] approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO[™], Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO[™] collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr

Follow us on Twitter: [@TransgeneSA](https://twitter.com/TransgeneSA)